Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp (ATNF) is a clinical-stage biotechnology company pioneering treatments for inflammatory diseases, fibrosis, and pain through advanced therapeutic platforms. This page serves as the definitive source for official news and developments across the company’s scientific research and blockchain-enabled iGaming initiatives.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, financial announcements, and strategic partnerships. Key focus areas include the company’s anti-TNF fibrosis research, synthetic cannabidiol analogs development, and expansion into blockchain-based gaming technology solutions.
All content is curated to provide accurate, compliance-focused information without speculative commentary. Regular updates ensure stakeholders maintain current awareness of ATNF’s progress in both biotechnology and digital innovation sectors.
Bookmark this page for direct access to press releases, earnings reports, and operational updates from 180 Life Sciences Corp. Check back frequently for the latest developments shaping this innovative dual-sector enterprise.
180 Life Sciences Corp. (NASDAQ: ATNF) announced significant progress in its operations and upcoming clinical trials in a letter from CEO Dr. James Woody. The company recently completed a $15M private placement, enhancing its financial standing to accelerate clinical programs for conditions like Dupuytren's contracture and frozen shoulder. All legacy liabilities from previous mergers have been addressed, allowing for timely financial reporting and compliance with Nasdaq. The firm also expanded its board with experienced professionals to bolster its strategic direction and execution.
180 Life Sciences Corp. (NASDAQ: ATNF) has completed a private placement of 2,500,000 shares and warrants, raising approximately $15 million. The shares were priced at $6.00 each, with warrants exercisable at $7.50. The net proceeds will support general corporate needs and R&D initiatives. Maxim Group LLC acted as the placement agent. These securities are unregistered and available only to accredited investors. The company is engaged in developing drugs for inflammatory diseases, leveraging expertise from prestigious universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $15.0 million through the sale of 2,500,000 shares of common stock and accompanying warrants. The combined purchase price is $6.00 per share and warrant, with warrants exercisable at $7.50 each for five years. The closing is anticipated on August 23, 2021, pending customary conditions. Maxim Group LLC is the placement agent. The offering is aimed at accredited investors and includes registration rights for resale of the shares.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Jagdeep Nanchahal, Professor of Hand Surgery, will present a keynote speech on September 9, 2021, at the British Society for Surgery of the Hand meeting. The presentation will cover his research on Dupuytren's disease and potential treatments targeting fibrotic processes. Dr. James Woody, CEO of 180 Life Sciences, expressed enthusiasm for sharing this significant scientific work with experienced clinicians.
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced that CEO Dr. James Woody and Professor Jagdeep Nanchahal will participate in the BTIG Virtual Biotechnology Conference from August 9-10, 2021. Their fireside chat is scheduled for August 10 at 1:00 PM ET. The conference will feature discussions on the company's innovative drug development targeting inflammatory diseases and fibrosis. A replay will be available for BTIG clients after the event. 180 Life Sciences is focused on addressing significant unmet medical needs in inflammation and pain.
180 Life Sciences Corp. (NASDAQ: ATNF) has selected a lead synthetic CBD analogue for clinical development targeting inflammation and pain. Collaborating with cannabis chemistry pioneer Professor Raphi Mechoulam and Sir Marc Feldmann, the company identified this non-psychoactive compound from numerous CBD derivatives. The analogue shows potential patent protection, strong preclinical efficacy, and scalability for GMP manufacturing. CEO Dr. James Woody expressed optimism for HUM-217's advancement in clinical trials, marking a significant progress in cannabinoid use in medicine.
180 Life Sciences Corp. (NASDAQ: ATNF) has regained compliance with Nasdaq's listing rule 5250(c)(1) after timely filing its annual and quarterly reports. After previous non-compliance notifications due to late filings of the 2020 Form 10-K and Q1 2021 Form 10-Q, the company submitted these documents on July 9 and July 19, 2021, respectively. Nasdaq confirmed compliance on July 19, 2021, indicating the matter is closed. 180 Life Sciences focuses on developing novel drugs targeting inflammatory diseases, leveraging expertise from top universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced on July 12, 2021, that it regained compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) after appointing new independent directors, thereby closing a compliance matter. The company had previously been notified of non-compliance by Nasdaq, which provided a 45-day period to submit a plan. After timely submission and an extension, the appointment of Pamela G. Marrone and Francis Knuettel II allowed the company to meet all requirements for continued listing.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled “Collagen VI as a driver and disease biomarker in human fibrosis” in the FEBS Journal. The study, authored by researchers from the University of Oxford, highlights the role of microfibrillar collagen VI in fibrotic diseases affecting vital organs. It identifies collagen VI cleavage fragments as potential biomarkers and therapeutic targets for fibrotic conditions. This publication underscores the company's commitment to advancing drug development for inflammatory diseases and fibrosis.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership is expected to enhance the company’s visibility, increase stock liquidity, and broaden its shareholder base as the Russell indexes are widely used benchmarks for investment strategies.
CEO Dr. James Woody highlighted this inclusion as a pivotal validation for the company, aiming to propel long-term shareholder value. The Russell indexes are benchmarked by approximately $10.6 trillion in assets, indicating significant market relevance.
